Tech Company Financing Transactions

Imara Inc. Funding Round

On 3/19/2019, Imara Inc. secured $63 million in Series B investment from Arix Bioscience, OrbiMed and Alexandria Venture Investments.

Transaction Overview

Company Name
Announced On
3/19/2019
Transaction Type
Venture Equity
Amount
$63,000,000
Round
Series B
Investors

Arix Bioscience (Lead Investor) (Mark Chin)

OrbiMed (Lead Investor) (David Bonita)

Alexandria Venture Investments

Bay City Capital

Lundbeckfond Ventures

New Enterprise Associates

Pfizer Venture Investments

RA Capital

Rock Springs Capital

Proceeds Purpose
Proceeds from the investment will be used to advance the company's lead program with IMR-687, currently in a multi-national Phase 2a clinical trial, into later-stage clinical trials, fund development of IMR-687 as a potential treatment for thalassemia, and expand the company's pipeline.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
700 Technology Sq. 3rd Floor
Cambridge, MA 02139
USA
Email Address
Overview
Imara Inc. (Nasdaq: IMRA), is dedicated to developing novel therapeutics for people living with sickle cell disease and other hemoglobinopathies. Sickle cell disease is a rare, genetic blood disease that causes red blood cells to sickle and become damaged, activating immune cells and blocking blood flow in capillaries, injuring many organs and causing daily pain.
Profile
Imara Inc. LinkedIn Company Profile
Social Media
Imara Inc. Company Twitter Account
Company News
Imara Inc. News
Facebook
Imara Inc. on Facebook
YouTube
Imara Inc. on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Rahul Ballal
  Rahul Ballal LinkedIn Profile  Rahul Ballal Twitter Account  Rahul Ballal News  Rahul Ballal on Facebook
Chief Medical Officer
ShiYin Foo
  ShiYin Foo LinkedIn Profile  ShiYin Foo Twitter Account  ShiYin Foo News  ShiYin Foo on Facebook
VP - Regulatory Affairs
Kevin Johnson
  Kevin Johnson LinkedIn Profile  Kevin Johnson Twitter Account  Kevin Johnson News  Kevin Johnson on Facebook


 

 

Browse more venture capital transactions:

Prev: 3/19/2019: Glossier venture capital transaction
Next: 3/19/2019: Ocular Therapeutix venture capital transaction

 

Share this article

 


Where The Data Comes From

We report on funding rounds that are announced publicly. VC investment data records on this site are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary